Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer

Isabelle Fournier1, Ashwini Venkata Bandi1, Sarah Hamidi2

  • 1Department of Head & Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Head & Neck
|September 2, 2025
PubMed
Abstract

Insights

Thyroid cancer with retropharyngeal lymph node (RPLN) metastases is rare. These metastases grow slowly, with larger ones often managed surgically with minimal long-term issues.

Area of Science:

  • Oncology
  • Head and Neck Surgery
  • Endocrinology

Background:

  • Retropharyngeal lymph node (RPLN) metastases are uncommon in thyroid cancer.
  • Optimal management strategies for these metastases remain underreported.

Purpose of the Study:

  • To analyze the management and outcomes of thyroid cancer patients with RPLN metastases.
  • To evaluate the growth patterns and treatment efficacy for RPLN metastases.

Main Methods:

  • Retrospective analysis of 167 thyroid cancer patients with RPLN metastases treated between 2000 and 2024.
  • Patients were categorized into active surveillance, surgical, and nonsurgical treatment groups.
  • Surgical approaches included transcervical, transoral robotic, and transoral methods.

Main Results:

  • RPLN metastases demonstrated slow growth, with a median annual increase of 3% in size.
  • Surgery was the primary treatment for metastases ≥1 cm, with low rates of post-operative dysphagia (11%) and velopharyngeal insufficiency (1%).
  • Nonsurgical options included radioactive iodine, radiation therapy, and systemic targeted therapy.

Conclusions:

  • Retropharyngeal lymph node metastases in thyroid cancer exhibit slow growth.
  • Surgical resection is effective for larger metastases (≥1 cm) with generally low long-term morbidity.

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
The Thyroid Gland01:23

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...